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Abstract: The objective of this article is to review published clinical data on diclofenac 
epolamine topical patch 1.3% (DETP) in the treatment of acute soft tissue injuries, such as 
strains, sprains, and contusions. Review of published literature on topical nonsteroidal anti-
inflammatory drugs (NSAIDs), diclofenac, and DETP in patients with acute soft tissue injuries 
was included. Relevant literature was identified on MEDLINE using the search terms topical 
NSAIDs, diclofenac, diclofenac epolamine, acute pain, sports injury, soft tissue injury, strain, 
sprain, and contusion, and from citations in retrieved articles covering the years 1978–2008. 
Review of published, randomized clinical trials and meta-analyses shows that topical NSAIDs 
are significantly more effective than placebo in relieving acute pain; the pooled average relative 
benefit was 1.7 (95% confidence interval, 1.5–1.9). In a limited number of comparisons, topical 
and oral NSAIDs provided comparable pain relief, but the use of topical agents produced lower 
plasma drug concentrations and fewer systemic adverse events (AEs). The physical–chemical 
properties of diclofenac epolamine make it well suited for topical use. In patients with acute 
soft tissue injuries treated with DETP, clinical data report an analgesic benefit within hours 
of the first application, and significant pain relief relative to placebo within 3 days. Moreover, 
DETP displayed tolerability comparable with placebo; the most common AEs were pruritus and 
other application site reactions. Review of published literature suggests that DETP is gener-
ally safe and well tolerated, clinically efficacious, and a rational treatment option for patients 
experiencing acute pain associated with strains, sprains, and contusions, and other localized 
painful conditions.
Keywords: diclofenac epolamine, topical analgesics, soft tissue injury, strains, sprains, 
contusions
Introduction
Muscle and musculoskeletal injuries, including sprains, strains, and contusions, comprise 
the majority of sports-related injuries.1–3 Sprains resulting from joint injuries are graded 
from I to III (mild to severe or by number and extent of ligaments involved) and most 
frequently affect the ankle.2 Sprains involve some degree of tearing and stretching of a 
supporting ligament,2 whereas strains refer to partial or complete tearing of the muscle–
tendon unit.1 Muscle contusions result from direct blunt trauma to muscle fibers, causing 
damage to the structure and function of the muscle.3 Each of these injuries produces local 
tissue inflammation, which causes pain, swelling, tenderness, limited mobility, and if 
sufficiently severe, disability.2,3 Moreover, initial treatment is similar depending on the 
severity of the injury. In general, initial treatment consists of rest, ice, compression, and 
elevation (RICE) and use of nonsteroidal anti-inflammatory drugs (NSAIDs) to limit Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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the extent of inflammation and pain and promote their early 
resolution.3–5 Depending on the injury, exercise and rehabilita-
tion are then used to restore strength and range of motion, and 
to promote proper healing.
Soft tissue injury
Acute ankle injuries account for an estimated 20% of all 
sports-related injuries and, of these, 85% are sprains typically 
involving inversion injuries to the lateral stabilizing liga-
ments (ie, anterior talofibular, calcaneofibular, and posterior 
talofibular).2,6–8 About 5% result from eversion injuries of the 
deltoid or medial ligaments.8 Conservative treatment with 
early weight bearing, bracing, and functional rehabilitation is 
generally the accepted approach for managing ankle sprains.2 A 
recent, systematic review of 24 high-quality clinical studies 
assessing the clinical course of ankle sprains revealed that 
there is a rapid decrease in patient reports of pain over the 
first 2 weeks following the injury.9 The initial pain and swell-
ing following an ankle sprain may limit the patient’s ability 
to perform the rehabilitation necessary for proper healing.10 
Moreover, fluid accumulation around the site of injury may 
exacerbate tissue damage, delay healing, and eventually lead 
to some degree of chronic disability.11 Accordingly, the initial 
emphasis of treatment after injury is to rapidly reduce pain 
and inflammation with RICE and use of NSAIDs during 
post-injury and the initial rehabilitation program.4 NSAIDs 
have been shown to effectively reduce pain and inflammation, 
improve function, and allow more rapid return to normal activ-
ity after ankle sprains.6 Although most ankle sprains do not lead 
to significant disability, residual pain is prevalent in 5%–33% 
of patients for up to 1 year after injury; in some patients, ankle 
symptoms, such as lateral instability, also persist.9
Acute muscle strains are partial tears of the tendinous inser-
tion into the muscle at the distal myotendinous junction, which 
are caused by excessive stretching while the muscle is being 
activated or during excessive use.5,12 In general, muscles that 
cross two or more joints and those with a higher percentage of 
type II muscle fibers are particularly susceptible to strains (eg, 
hamstring, quadriceps, gastrocnemius).1,5 The degree of dam-
age depends on how much force was placed on the muscle in 
relation to the muscle resistance and, in turn, is associated with 
the magnitude of pain and inflammation.5 Hemorrhage and 
hematoma formation are commonly seen in acute strains. Treat-
ment is based on the severity of the injury and includes RICE 
and NSAIDs in the acute setting.3,5 During the healing phase, 
stretching and strengthening exercises are often added.3
Contusions resulting from direct blunt trauma to muscle 
fibers may cause capillary rupture, bleeding, hematoma 
  formation, and eventually an intense inflammatory response.5 
Mild contusions cause localized tenderness with little, if any, 
loss in range of motion, whereas severe contusions present 
with marked tenderness and swelling and less than 50% 
range of motion.5 RICE is used initially to limit the range of 
motion of the affected extremity and minimize the risk of 
hemorrhage, and NSAIDs are introduced in the acute set-
ting to provide early resolution of pain and inflammation.3 
This is followed by restoration of active and active-assisted 
range-of-motion exercises and, subsequently, by functional 
rehabilitation and resistance exercises.5
Use of oral NSAIDs in the 
management of soft tissue injuries
NSAIDs provide the cornerstone for the treatment of acute 
pain and inflammation.11,13 Clinical studies in patients with 
soft tissue injuries demonstrate that NSAIDs provide symp-
tomatic relief of pain and allow faster recovery and return 
to normal activities when compared with placebo.11,13 On the 
basis of these benefits, NSAIDs have a role in the short-term 
management of soft tissue injuries. They should be used 
judiciously for as short a period as possible and at the low-
est possible effective dose, based on the type of injury and 
level of dysfunction and pain.13 In general, a short course of 
NSAID therapy lasting 3–7 days after ligament sprains and 
muscle injury is likely to be beneficial, but the effects of 
their long-term use remain controversial.13 Use of NSAIDs 
in acute tendonitis and tenosynovitis is also reasonable in 
the days immediately after injury, when some amount of 
inflammation is expected.13
The analgesic and anti-inflammatory effects of NSAIDs 
are mediated via their inhibition of prostaglandin biosyn-
thesis. Traditional NSAIDs, such as diclofenac, inhibit both 
cyclooxygenase-1 (COX-1) and COX-2 isoenzymes, which 
are rate-limiting enzymes in the prostaglandin biosynthetic 
pathway.14,15 At pharmacologically effective doses, systemic 
NSAID therapy may produce a variety of adverse events 
(AEs) related to the inhibition of prostaglandin synthesis 
involved in maintaining normal physiological processes. For 
example, inhibition of the COX-1 isoenzyme in gastrointes-
tinal mucosa is known to be responsible for the increased 
risk of gastrointestinal AEs associated with traditional 
NSAID use. This led to the design and development of the 
COX-2–selective inhibitors, such as celecoxib and etoricoxib, 
which display reduced risk of gastrointestinal AEs compared 
with traditional NSAIDs.16
Gastrointestinal toxicity, including serious gastrointes-
tinal perforations, ulcers, or bleeding, can often limit the Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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use of traditional NSAIDs.17 Poor tolerability due to upper 
gastrointestinal symptoms, often categorized as dyspepsia, 
is a significant cause of treatment discontinuation.18 The 
prevalence of dyspepsia in patients treated with traditional 
NSAIDs can be high, ranging from 5%–50%.19 Due to the 
role of the COX-2 isoenzyme in renal prostaglandin biosyn-
thesis, both traditional and selective NSAIDs are associated 
with renovascular AEs; risk may be increased in agents with 
a longer half-life.20,21
The AEs associated with oral NSAID therapy also have a 
significant economic consequence. A retrospective database 
analysis found that direct medical costs were increased by 
nearly $1 per day due to gastrointestinal events related to 
NSAID use in an elderly population.22 Other studies have 
shown that reducing gastrointestinal events by switching from 
oral NSAIDs to topical agents would reduce medical costs.23
Topical NSAIDs
General
Topical NSAIDs are designed to be applied over the site 
of injury and exert their analgesic and anti-inflammatory 
effects in the underlying superficial, musculoskeletal soft 
tissue. Topical NSAIDs work locally and are not dependent 
on systemic absorption and subsequent redistribution into 
peripheral tissues.24 Accordingly, topical application of 
NSAIDs differs from transdermal drug delivery, which is 
designed to provide active drug to the systemic circulation 
and exert effects at sites distant from the application site.25
Benefits
Topical application of NSAIDs offers a number of 
potential benefits compared with oral systemic deliv-
ery. NSAIDs, when administered topically, are gener-
ally well tolerated with AEs mainly limited to mild skin 
irritation – erythema, dermatitis, and pruritus – that resolves 
upon discontinuation.26 Topical administration results in sig-
nificantly lower systemic drug exposure, reducing the risks 
of dose-dependent NSAID-associated AEs.27 In the event of 
an untoward effect, the topical dose can be easily terminat-
ed.25 Topical application can also avoid extensive first-pass 
metabolism, as is seen with oral diclofenac formulations. 
Other advantages of topical drugs include direct access, 
delivery, localization at site of action, and the option of 
prolonged use;28–30 ease of use may lead to improved patient 
compliance and adherence to the prescribed regimen.31–33 
Moreover, topical drugs may be a viable option for patients 
who cannot use oral medications.25
Pharmacokinetics
Pharmacokinetic studies, which included diclofenac, 
ketorolac, and ketoprofen in various formulations, includ-
ing gels, ointments, and patches, found that peak plasma 
NSAID concentrations following topical application are 
0.2%–8% of those seen after oral dosing.15 Additionally, the 
time to achieve peak levels following topical application 
was approximately 10-fold longer than the corresponding 
time following an equivalent oral dose and ranged from 2.2 
to 23 hours.15 With multiple topical doses, steady state is 
achieved within 2–5 days, and Cmax is about 2.5 times higher 
than Cmax following a single topical dose; however, serum 
concentrations remain .90% lower than those achieved 
after oral NSAIDs.34,35 Application of a diclofenac epolamine 
topical patch (DETP) in 10 healthy male volunteers (twice 
daily for 7 days) produced peak plasma drug levels nearly 
100 times lower than those achieved after a single 50-mg, 
oral dose of diclofenac with area under curve values that 
were 10–20 times lower over 48 hours.36,37
Efficacy
The efficacy of topical NSAIDs was assessed in a meta- 
analysis of 61 randomized controlled trials that involved a 
total of  7,727 patients with acute pain.27 Trials were included 
if a topical NSAID was compared with placebo, another 
topical NSAID, or an oral NSAID in recent soft tissue 
injury, sprain, strain, or trauma. Of 37 placebo-controlled 
trials, 27 showed that the topical NSAID was significantly 
superior to placebo, and 9 additional studies showed a trend 
favoring the topical drug (Figure 1).27 Overall, the pooled 
relative benefit was 1.7 (95% confidence interval [CI]: 
1.5–1.9), and the number needed to treat (NNT) to achieve 
a successful outcome with topical NSAIDs was 3.9 (95% 
CI: 3.4–4.4). The 24 studies that compared topical NSAIDs 
with one another or with an oral NSAID found no difference 
in efficacy between treatments.27 Overall, the incidence of 
local AEs (2.6% vs 3.0%), systemic AEs (0.8% vs 0.7%), 
and AEs leading to withdrawal of treatment (0.6% vs 0.4%) 
did not differ significantly between the topical NSAIDs and 
placebo.27 This meta-analysis also included 25 additional 
trials involving 2,433 patients with chronic pain conditions, 
including osteoarthritis and other rheumatologic disorders.27 
In this analysis, topical NSAIDs were more effective than pla-
cebo, with a pooled relative benefit of 2.0 (95% CI: 1.5–2.7) 
and an NNT of 3.1 (95% CI: 2.7–3.8).27
A subsequent meta-analysis evaluated 26 randomized 
controlled trials involving 2,853 adults with acute pain 
resulting from strains, sprains, or sports injuries.38 Topical Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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NSAIDs demonstrated significantly better analgesic efficacy 
than placebo in 19 of the 26 trials and overall produced a rela-
tive benefit of 1.6 (95% CI: 1.4–1.7) and an NNT of 3.8 (95% 
CI: 3.4–4.4).38 When only high-quality and/or high-validity 
studies were retained in the meta-analysis, the superiority 
of topical NSAIDs over placebo was still evident with NNT 
values of 3.7–4.0. Five topical NSAIDs were evaluated in at 
least 3 clinical trials (ketoprofen, ibuprofen, felbinac, piroxi-
cam, and indomethacin) and all were found to be superior to 
placebo.38 Consistent with the first meta-analysis, incidence of 
local AEs (4.4% vs 4.7%), systemic AEs (2.8% vs 2.4%), and 
AE–related withdrawals (0.8% vs 0.7%) was similar between 
topical NSAIDs and placebo.38 Together, these analyses dem-
onstrate that topical NSAIDs are effective and well tolerated 
in the short-term treatment of acute soft tissue injuries.
Limitations
Several limitations are inherent to the use of topical NSAIDs. 
Most notably, since systemic exposure is minimized, these 
formulations are only effective for the treatment of localized 
pain at the site of application. Due to the continued contact of 
the formulation with the skin, localized skin reactions, such as 
irritant dermatitis and erythema, are observed.27,38 However, 
as noted previously, meta-analyses have shown that these 
local AEs occur only in a small minority of patients treated 
for acute soft tissue injuries with topical NSAIDs.27,38
Diclofenac
Diclofenac is a traditional NSAID that possesses anti-
inflammatory, analgesic, and antipyretic properties through 
inhibition of COX isoenzymes and blockade of prostaglandin 
synthesis.39 It is among the most widely prescribed NSAIDs 
worldwide,21 and unlike other traditional NSAIDs, such as 
ibuprofen and naproxen, does not interfere with the anti-
platelet effects of low-dose aspirin.21,40,41 Diclofenac also has 
the potential to affect polymorphonuclear leukocyte func-
tion in vitro, which may contribute to its anti-inflammatory 
effects by reducing the ability of these cells to infiltrate into 
an inflammatory site and produce damaging oxygen radicals 
and proteases.39 Noncomparative clinical studies showed that 
oral diclofenac sodium has a rapid onset of action in treat-
ing soft tissue injuries, including acute strains, sprains, and 
contusions, with doses of 75–150 mg/d producing clinical 
improvement in as little as 2–3 days.42 Comparative clinical 
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Figure 1 Success rates with topical nonsteroidal anti-inflammatory drugs (NSAIDs) vs topical placebo in the treatment of acute (open circles) and chronic (filled squares) 
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trials demonstrated that diclofenac sodium administered as a 
conventional enteric-coated tablet formulation was at least as 
effective and well tolerated as other NSAIDs in patients with 
acute soft tissue injuries.43–45 In a randomized controlled trial 
of 139 patients with acute sports injuries, diclofenac sodium 
150 mg/d allowed an earlier return to sport-playing fitness than 
aspirin 3.6 g/d,44 and in another randomized controlled trial of 
151 patients with acute strains, diclofenac sodium 100 mg/d 
was as effective as indomethacin 100 mg/d but produced fewer 
AEs and fewer discontinuations due to AEs.43
Diclofenac dispersible, a drinkable formulation of 
diclofenac, also has been shown to provide a rapid onset 
of pain relief in patients with acute soft tissue injuries.46 In 
a randomized, blinded study of 48 adults with acute minor 
sports injuries and moderate to severe pain on movement, 
a single 50-mg dose of diclofenac dispersible was more 
effective than 500 mg of naproxen granular in reducing pain 
intensity on movement and on pressure during the 4-hour 
period after dosing (P # 0.04), and in producing rapid pain 
relief in the first hour (P = 0.034 at 15 minutes).47 Both 
agents were equally well tolerated.
Regardless of the formulation, the most common AEs 
associated with oral diclofenac have been gastrointestinal 
effects, including abdominal pain or cramping, constipation, 
indigestion, and nausea and, less frequently, abdominal disten-
tion, flatulence, vomiting, and upper and lower gastrointestinal 
complicated events including bleeding.16,18,39,48 The transient 
effect of oral antiarthritic doses on inhibition of platelet 
aggregation49 most likely accounts for the lower rates of ulcer 
complications associated with diclofenac use compared with 
other traditional NSAIDs.50–52 An analysis of data from clinical 
trials involving more than 85,000 patients, as well as postmar-
keting surveillance, found that oral diclofenac produces AEs 
in about 12% of patients and gastrointestinal AEs in 8%–10% 
of patients; approximately 1.5%–2% of patients discontinue 
treatment due to AEs.39 However, trials evaluating NSAID and 
COX-2 inhibitor used in patients with rheumatoid arthritis and 
osteoarthritis have reported discontinuation rates due to gas-
trointestinal AEs of 6–19 events per 100 patient-years.16,18,48 In 
a randomized controlled trial, the cumulative discontinuation 
rate due to gastrointestinal AEs in 3,518 patients receiving 
diclofenac sodium 50 mg three times daily for osteoarthritis 
was 19.2 events per 100 patient-years.18
Considerations for topical 
administration of diclofenac
The stratum corneum – a heterogeneous structure con-
taining protein (keratin), water, and lipids (cholesterol, 
  phospholipids) – plays a crucial role in controlling the 
percutaneous absorption of drug molecules.53,54 Other key 
factors affecting absorption include drug-related factors 
(eg, lipophilicity, water solubility, molecular size, and 
vehicle), application conditions (open vs closed), and skin 
integrity, which is affected by disease, body site, and age.53
Hydration of the stratum corneum is an important deter-
minant of drug absorption. Free diclofenac displays very 
low water solubility due to its high hydrophobicity and 
lipophilicity and, therefore, is paired with a salt to facilitate 
topical absorption.54,55 Several different salts of diclofenac 
are used in commercial products, including sodium, potas-
sium, diethylamine, and N-(2-hydroxyethyl) pyrrolidine (also 
called epolamine) salts, and they have been considered for 
both oral and topical administration.56
Several formulations of diclofenac have also been devel-
oped, including gel, patch, and lotion formulations, which 
differ in their pharmacokinetics and systemic exposure. 
For example, a diclofenac aqueous gel formulation has 
been shown to produce Cmax levels more than double those 
seen with an emulsion gel.57,58 The topical solution, a 1.5% 
weight/weight diclofenac sodium topical solution, utilizes 
the permeation enhancer dimethyl sulfoxide (DMSO). Con-
tinuous application of the solution (80 drops 4 times daily 
for 7 days) is associated with a mean Tmax of 4.0 hours and 
a mean Cmax of 19.4 ng/mL, while continuous application of 
the diclofenac sodium 1% gel (4 g 4 times daily for 7 days) 
is associated with a median Tmax of 14 hours and a mean Cmax 
of 15 ng/mL.59,60 Additionally, continuous use of the topical 
solution resulted in approximately one-third of the systemic 
exposure seen after 1 month of applying a 3% diclofenac 
sodium gel twice daily.59
Of the available diclofenac formulations, the epolamine 
salt of diclofenac offers specific advantages for topical 
administration. The surfactant property of diclofenac epol-
amine improves hydration of the stratum corneum, thereby 
lowering surface tension at the interface between the skin 
and the topical pharmaceutical preparation, which favors 
drug absorption through the skin.54 The use of epolamine 
as the ion-pairing agent enhances lipophilicity and water 
solubility compared with simple sodium or potassium salts of 
diclofenac and the permeation of diclofenac through the stra-
tum corneum and epidermis.54–56,61,62  This was demonstrated 
by a direct comparison that showed the mean absorption rate 
(ka) of diclofenac epolamine into plasma was 1.4-fold greater 
than that of diclofenac sodium (P , 0.001).63 Interaction 
of the ion pair with cell membrane lecithins has also been 
demonstrated to enhance membrane permeability, further Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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facilitating absorption of diclofenac through the external 
layer of the skin.54,64 This property omits the need for per-
meation enhancers, such as DMSO, which is used in other 
topical diclofenac formulations.65,66 When applied topically 
in a patch, diclofenac epolamine produces consistent and sus-
tained drug release for 12 hours, with systemic drug exposure 
being 10–20 times lower over 48 hours than that following a 
single oral diclofenac dose.36 A recent report has indicated 
that, over 12 hours, plasma concentrations of diclofenac after 
twice-daily dosing for 4 consecutive days with the patch for-
mulation of diclofenac epolamine were ,1% of those after a 
single 50-mg dose of oral diclofenac sodium enteric-coated 
tablets.37,67 The patch formulation of diclofenac epolamine 
has been shown to have a bioavailability of approximately 
30% relative to a 1% gel formulation following continuous 
use over 7 days. The administration of diclofenac epolamine 
1% gel led to a mean Tmax of 3.1 hours and mean Cmax of 
28.1 ng/mL, while the patch formulation led to a mean Tmax 
and Cmax of 5.4 hours and 17.4 ng/mL, respectively.36
Pharmacokinetic studies have shown that topically 
applied diclofenac not only penetrates the stratum corneum 
and deeper skin layers, but also reaches joints, muscles, and 
synovial fluid in sufficiently high concentrations to exert, 
in principle, local therapeutic activity.68,69 In one study, the 
plasma bioavailability of a topical 4% spray gel of diclofenac 
sodium applied to a defined area on the thigh was 50 times 
lower than oral administration of diclofenac sodium tablets. 
However, bioavailability in subcutaneous adipose tissue and 
skeletal muscle tissue was 2–3 times higher with topical 
dosing than with oral dosing.70 In healthy volunteers, topi-
cal diclofenac was shown to improve the pain threshold of 
the quadriceps muscle, providing further evidence of deep 
penetration after topical application.71
Efficacy and tolerability  
of topical diclofenac
The efficacy and tolerability of various topical diclofenac 
formulations, including 1.5% diclofenac sodium solution, 
1.16% diclofenac diethylamine gel, 140 mg diclofenac 
hydroxyethylpyrrolidine patch, and 2% diclofenac lecithin 
organogel, in 19 clinical trials in more than 3,000 patients 
have been recently reviewed.72 Topical diclofenac agents 
have been shown to provide effective analgesia for both 
acute and chronic pain, including indications such as blunt 
impact injuries, soft tissue injuries, sprains, osteoarthritis, and 
epicondylitis.72 Efficacy of topical diclofenac was   comparable 
with other topical NSAIDs (such as indomethacin gel, 
  ketoprofen gel, piroxicam gel, and indomethacin patch) and 
some oral NSAIDs (diclofenac, naproxen, ibuprofen) in 
relieving acute and chronic pain.72
Topical diclofenac formulations are well tolerated; local 
skin irritation was the most frequent AE and was easily 
resolved. Incidence of systemic AEs has been shown to be 
similar to placebo,65 and the incidence of gastrointestinal 
AEs has been shown to be lower than oral diclofenac (35% 
vs 48%, P = 0.0006).73 The use of DMSO to enhance per-
cutaneous absorption of diclofenac sodium may contribute 
to the localized skin irritation, and in some patients, cause 
halitosis and body odor.65
Unlike conventional topical formulations (eg, gels), 
patches permit constant delivery of the active agent into the 
affected area by means of an occlusive bandage that promotes 
controlled and slow release of the drug.36,74 Occlusion has a 
favorable impact on drug absorption, sometimes improving 
penetration by 200%–300%, which likely reflects changes 
in skin hydration and temperature.30
Diclofenac epolamine topical patch
The DETP 1.3% (FLECTOR® Patch; King Pharmaceuticals® 
Inc, Bristol, TN), the first topical NSAID patch approved in 
the United States for the treatment of acute pain of minor 
strains, sprains, and contusions, is a topical delivery system 
composed of an adhesive material containing 1.3% diclofenac 
epolamine, which is applied to a nonwoven polyester felt 
backing.75 The 10 cm × 14 cm patch is covered by a poly-
propylene film release liner that is removed before the patch 
is applied to the skin. Each adhesive patch contains 180 mg 
of diclofenac epolamine and inactive excipients, which 
enhance skin hydration and facilitate plaster adherence. Fol-
lowing application of  DETP on the upper arm, peak plasma 
concentrations of 0.7–6.0 ng/mL were found at 10–20 hours 
with plasma concentrations increasing to 1.3–8.8 ng/mL after 
twice-daily application of DETP for 5 days.75 Once absorbed, 
diclofenac is highly bound to serum albumin (.99%), with a 
half-life of approximately 12 hours.75 Diclofenac undergoes 
metabolism and subsequent urinary and biliary excretion of 
the sulfate and glucuronide conjugates.75
DETP is indicated for the topical treatment of acute 
pain resulting from minor strains, sprains, and contusions.75 
One patch is applied to the painful area and changed every 
12 hours.75
Efficacy and tolerability of DETP  
in treating strains, sprains, and contusions
The efficacy and tolerability of DETP in relieving acute pain 
due to minor sports injury were evaluated in a   multicenter, Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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Figure 2 Comparison of diclofenac epolamine topical patch (DETP) and placebo in reducing pain on movement in patient with acute ankle sprains. Pain was measured on 
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randomized, placebo-controlled, parallel-group study of 
222 adults who were injured within the 72 hours prior to 
study enrollment.76 The patch was applied directly over the 
injured site and changed twice daily for 2 weeks. Measures 
of pain intensity were evaluated on days 3, 7, and 14. DETP 
was significantly more effective than placebo in relieving 
pain during daily activities as measured by a 100-mm visual 
analog scale (VAS) and analyzed by the summed pain inten-
sity difference during clinic visits on days 3 (P = 0.036) and 
14 (P = 0.048).76 In addition, DETP was more effective than 
placebo based on daily diary recordings on days 3, 7, and 
14 (P # 0.044). DETP was well tolerated; the incidence 
and intensity of AEs were comparable with those seen with 
the placebo patch. Rash was reported by 5% of patients in 
each treatment group, whereas pruritus was less common 
with DETP than placebo (5% vs 17%).76
Comparable results were reported in a randomized, 
placebo-controlled, multicenter study conducted in the 
United States, which included 365 patients with minor 
sports injuries occurring within the previous 72 hours and 
pain $ 5 on a numeric pain scale from 0 to 10.77 DETP 
significantly reduced the median time to pain resolu-
tion (primary end point) compared with placebo (8.8 vs 
12.4 days, P = 0.009). In addition, DETP significantly 
reduced spontaneous pain compared with placebo, start-
ing on day 6 and continuing until day 13 (all P , 0.05). 
The tolerability of DETP was comparable with placebo, 
with no difference between treatments in the incidence or 
distribution of AEs.77
DETP was also assessed in a single-center, open-label 
study involving 101 patients with minor sports and   overload 
injuries.78 DETP was applied topically twice daily for 14 days. 
Spontaneous pain – measured using a 4-point verbal scale 
ranging from 0 (no pain) to 3 (severe pain) – was reduced 
by 28% on day 7 and 60% on day 14.78 Comparable results 
were found for spontaneous pain, measured using a 10-cm 
VAS, and pain on pressure, evaluated using the 4-point verbal 
scale. DETP was well tolerated, with all patients rating the 
tolerability of DETP to be good to excellent.78
Two 7-day, multicenter, randomized controlled studies 
evaluated DETP in the treatment of acute pain due to ankle 
sprains. In the first study, which enrolled 140 patients with 
benign ankle sprains, DETP significantly reduced spontane-
ous pain starting as early as 3 hours (P = 0.005) and con-
tinuing through day 3 (P = 0.004) and day 7 (P = 0.0008).79 
DETP also reduced all secondary efficacy parameters (pain 
at rest and upon palpation, provoked passive pressure, and 
monopedal support) compared with placebo starting on day 
3 and persisting through day 7. Similarly, DETP produced 
greater anti-inflammatory activity than placebo assessed by 
the decrease in edema as measured from the perimalleolar 
perimeter. Tolerability was judged to be good or very good 
by physicians in 69 of 70 patients in each group.79
In the second study, 134 patients with ankle sprains occur-
ring within the previous 48 hours and having pain $ 50 mm 
on a 100-mm VAS were randomly allocated to DETP or 
placebo group.80 DETP was superior to placebo in reducing 
pain on movement starting 4 hours after the first application 
(P , 0.02) and continuing up to the end of the 7-day study 
period (P , 0.01; Figure 2). DETP was also superior to pla-
cebo in improving the secondary study end points, including 
pain during passive stretch, on pressure, and when standing Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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on one foot, by day 3 (P = 0.003, P = 0.007, P = 0.002, 
respectively).80 No AEs were reported in this study.
Efficacy and tolerability of DETP  
in other painful conditions
DETP administered for 14 days to patients with epicondylitis 
significantly reduced the percentage of patients report-
ing moderate to intense pain compared with baseline and 
placebo (P , 0.05).81 At study completion, nearly a third 
fewer patients treated with DETP continued to experience 
intense pain compared with placebo. Pain on pressure 
was also significantly improved by DETP compared with 
placebo starting on day 7.81 DETP was well tolerated, with 
mild, temporary skin reactions seen in 1 patient in each 
study group.
DETP or placebo was applied topically every 12 hours 
for 2 weeks to 60 patients with periarticular tendinous disor-
ders (eg, tendonitis, epicondylitis), rheumatologic disorders 
(eg, osteoarthritis, rheumatoid arthritis), or extra-articular 
pathologies (eg, fibrositis).74 In the subgroup with periarticu-
lar disorders, spontaneous pain, pain on pressure, and peri-
articular swelling improved progressively with DETP, with 
significant differences compared with placebo first seen on 
day 5 (P # 0.05) and persisting to the end of the 14-day treat-
ment period (P # 0.01).74 On day 7, the efficacy of DETP was 
judged to be good or excellent by 70% of patients compared 
with only 7% in the placebo group. The efficacy of DETP 
was also superior to placebo in the subgroup with fibrositis 
starting on day 7.74 DETP applied twice daily was compared 
with 2 g of diclofenac diethylammonium emulgel 1.16% 
applied 4 times per day for 14 days to patients with localized 
periarticular or tendinous disorders.82 Although both topical 
agents significantly improved spontaneous pain and pain 
on pressure, the effects of DETP were significantly greater 
than those of diclofenac diethylammonium (P , 0.001).82 
  Furthermore, the patient and physician assessments of 
treatment efficacy favored DETP (both P , 0.0001). Both 
treatments were similarly well tolerated irrespective of the 
site or nature of the localized inflammation.
Safety profile
The most common AEs with DETP in placebo-controlled 
clinical trials were application site reactions (11%), most 
commonly pruritus (5%), occurring at rates comparable 
with placebo (12% and 8%, respectively).75 DETP should 
not be applied to nonintact or damaged skin including areas 
with, for example, dermatitis, eczema, lesions, burns, or 
wounds.75
Gastrointestinal AEs were reported in 9% of patients 
treated with DETP compared with 6% of those who received 
placebo,75 representing a three fold to five fold improvement 
over the rates for traditional oral NSAIDs.50 Dyspepsia was 
reported in only 1% of patients treated with DETP. Regard-
less, DETP should be used with caution in patients with a 
history of ulcers or gastrointestinal bleeding.75
As with other NSAIDs, DETP has boxed warnings for 
cardiovascular and gastrointestinal risk and should be used 
with caution in patients with hypertension, congestive heart 
failure, and fluid retention; it is contraindicated in the treat-
ment of perioperative pain following coronary artery bypass 
graft surgery.75 Treatment with DETP is not recommended 
in patients with advanced renal disease but, if initiated, 
close monitoring of renal function is advised. Patients who 
develop abnormal liver function tests, anemia, or abnormal 
platelet function during use should also be monitored and 
further evaluated.
The general precautions recommended for all NSAIDs 
also apply to DETP. DETP should not be taken by patients 
who have shown hypersensitivity to diclofenac or other 
NSAIDs, and since there are no well-controlled studies in 
pregnant women, the benefit and risk should be carefully 
weighed.75
The potential for drug–drug interactions should be con-
sidered when DETP is used by patients who are simultane-
ously using other drugs.75 This may be especially relevant 
in older patients who may have age-related physiological 
changes and comorbid conditions that require concomitant 
medications.83 In general, NSAIDs may reduce the antihy-
pertensive effects of angiotensin-converting enzyme inhibi-
tors and the natriuretic effects of furosemide and thiazide 
diuretics. NSAIDs can increase exposure to lithium and 
methotrexate, raising the possibility for greater toxicity 
by these agents, and augment the anticoagulant effects of 
warfarin, thereby raising risk of gastrointestinal bleeding. 
In addition, concomitant use of aspirin reduces binding of 
diclofenac to serum proteins, thereby increasing the pos-
sibility of AEs.75
A large proportion of the adult population in the United 
States is currently treated with low-dose aspirin for car-
diovascular prophylaxis. In a recent Internet survey of 
1,000 general practitioners in the United States, 85% of 
providers indicated that more than 25% of their patients 
were taking aspirin for preventive reasons.84 The concomi-
tant use of low-dose aspirin and oral NSAIDs has been 
associated with an increased risk of serious gastrointestinal 
AEs.19 Although the use of gastroprotective agents, such as Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
231
Diclofenac epolamine topical patch
proton pump inhibitors, appears to lower the risk of serious 
gastrointestinal AEs, not all patients on NSAID therapy 
receive these agents.84 Therefore, patients currently being 
treated with low-dose aspirin and requiring concomitant 
NSAID therapy should be prescribed the lowest effective 
dose for the shortest time period. In this regard, topical 
NSAID formulations allow for the lowest systemic exposure, 
providing effective analgesic and anti-inflammatory clini-
cal efficacy for the treatment of acute strains, sprains, and 
contusions. However, it is unlikely that controlled clinical 
studies will be performed to specifically examine the risk of 
NSAID-associated AEs in patients being treated for acute 
pain with topical NSAIDs and low-dose aspirin, as studies 
involving the treatment of acute pain usually include small 
sample sizes compared with those needed to adequately 
address this question.
Conclusion
Topical NSAIDs are effective in the treatment of acute 
pain due to soft tissue injuries. These agents are designed 
to work locally in the soft tissue and on peripheral nerves 
underlying the site of application and are not designed to be 
absorbed systemically in an appreciable amount. Controlled 
clinical trials have demonstrated that DETP is clinically 
effective in treating acute pain due to soft tissue injuries, 
producing clinical benefit within several hours of the first 
application and significant pain relief relative to placebo 
that is measurable within 3 days and maintained through 
the end of a 7-day to 14-day treatment period. Notably, 
DETP is well tolerated, with the incidence and intensity 
of AEs being comparable with placebo. On the basis of 
available evidence, DETP represents a generally safe and 
well-tolerated, clinically effective option for treating acute 
pain associated with strains, sprains, and contusions, along 
with other localized painful inflammatory conditions.
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